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Abstract
Aims Residual pulmonary congestion at hospital discharge can worsen the outcomes in patients with heart failure (HF) and
can be detected by lung ultrasound (LUS). The aim of this study was to analyse the prevalence of subclinical pulmonary con-
gestion at discharge and its impact on prognosis in patients admitted for acute HF.
Methods and results This is a post-hoc analysis of the LUS-HF trial. LUS was performed by the investigators in eight chest
zones with a pocket device. Physical exam was subsequently performed by the treating physicians. Primary outcome was a
combined endpoint of rehospitalization, unexpected visit for HF worsening or death at 6- month follow-up. Subclinical pulmo-
nary congestion at discharge was defined as the presence of ≥5 B-lines in LUS in absence of rales in the auscultation employing
the area under the ROC curve. At discharge, 100 patients (81%) did not show clinical signs of pulmonary congestion. Of these,
41 had ≥5 B-lines. Independent factors related with the presence of subclinical pulmonary congestion were anaemia, higher
New York Heart Association (NYHA) class, and N terminal pro brain natriuretic peptide (NT-proBNP). After adjusting by propen-
sity score analysis including age, renal insufficiency, atrial fibrillation, NYHA class, NT-proBNP levels, clinical congestion, and the
trial intervention, the presence of subclinical pulmonary congestion at discharge was a risk factor for the occurrence of the
primary outcome (hazard ratio 2.63; 95% confidence interval: 1.08–6.41; P = 0.033).
Conclusions Up to 40% of patients considered ‘dry’ according to pulmonary auscultation presents subclinical congestion at
hospital discharge that can be detected by LUS and implies a worse prognosis at 6- month follow-up. Comorbidities, high
values of natriuretic peptides, and higher NYHA class are the factors related with its presence.
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Introduction
Pulmonary congestion is a key feature in the pathophysiology
of acutely decompensated heart failure (ADHF), and residual
congestion at the time of hospital discharge is one of the main
contributors of readmission risk.1–3 Moreover, unacceptably
high rates of hospital readmission have been observed even
in patients without detectable clinical congestion,4 possibly
because of the persistence of subclinical pulmonary fluid over-
load. Typically, pulmonary congestion has been assessed
through symptoms and signs from physical examination, as
well as other tools such as biomarkers or chest X-ray.5 How-
ever, these methods are subject to significant inter-observer
variability and can be unreliable.6
Lung ultrasound (LUS) has emerged as a simple, non-
invasive, semi-quantitative tool for the detection of
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pulmonary congestion. This technique is based on the obser-
vation of vertical echogenic lines arising from the pleura (B-
lines) in a pattern that resembles the tail of a comet. The
number of B-lines has been found to be a reliable indicator
of the presence of extravascular lung water and has allowed
the identification of heart failure (HF) patients with a worse
prognosis.7–10 In addition, the LUS-HF trial has recently
showed that the assessment of pulmonary congestion by
LUS helps to guide treatment in patients with HF and to im-
prove their prognosis.11 However, there is a paucity of data
about the prevalence of subclinical pulmonary congestion
and its potential prognostic impact in patients discharged
without clinically lung fluid overload.
Thus, the aim of this study was to identify the prevalence
of subclinical pulmonary congestion at discharge, related fac-




This is a post-hoc analysis of the LUS-HF trial.11 Briefly, this
was a single-centre, single-blind, randomized clinical trial
evaluating whether a LUS-guided follow-up protocol im-
proves the outcomes in patients with HF. Patients were re-
quired to be aged ≥18 years and to have been hospitalized
for ADHF defined by shortness of breath, pulmonary conges-
tion on X-ray, and high N terminal pro brain natriuretic pep-
tide (NT-proBNP) values in the first 24 h of admission (cut-
off values: 450 ng/L in patients aged <50 years; >900 ng/L
in patients aged 50–75 years; >1800 ng/L in patients aged
>75 years). Exclusion criteria were inability to attend
follow-up visits, a life expectancy of <6 months,
haemodialysis, and the presence of severe lung disease
preventing LUS interpretation. The primary endpoint was a
composite of urgent visit, hospitalization for worsening HF,
and death during follow-up. Urgent visits for worsening HF
were defined as visits to the emergency department or un-
scheduled visits to the HF unit as a result of signs and/or
symptoms of worsening HF that required intravenous diuretic
treatment or diuretic increase with an hospital stay of <24 h.
Hospitalization for worsening HF was defined as a stay in hos-
pital for >24 h mainly as a result of signs and/or symptoms of
worsening HF. Secondary outcomes were the separate com-
ponents of the primary outcome. Visits were scheduled in
the HF clinic at 14, 30, 90, and 180 days after discharge. Eligi-
ble patients were randomized at discharge to either the LUS
non-guided (control) group or the LUS-guided group. LUS
was performed in both groups, but the result was only avail-
able to the treating physician in the LUS-guided arm. In both
groups, patients were treated according to current
guidelines,12 but treating physicians were encouraged to
modify diuretic therapy in accordance with the number of
B-lines in the LUS-guided group. The protocol was approved
by the ethics committee of the study institution, and it was
conducted in accordance with the principles of the Declara-
tion of Helsinki. Written informed consent was obtained from
all patients.
Lung ultrasound protocol
Lung ultrasound studies were performed with a pocket
ultrasound device (VScan®; GE Healthcare, Chicago, IL, USA)
with a cardiac phased array transducer. According to a cur-
rent expert consensus document,13 LUS was recorded at four
sites in each hemithorax with the transducer perpendicular to
the ribs and at a 16 cm imaging depth being the patient in the
semi-recumbent position (Figure 1). Video clips were ob-
tained and stored for later review. The number of B-lines re-
ported in real time was the sum of the B-lines visualized in
each thoracic site, and investigators were blinded to clinical
findings. Additional investigations assessing clinical conges-
tion (physical exam and natriuretic peptides) were performed
at the same time as the LUS studies by the treating
physicians.
Subclinical pulmonary congestion
Subclinical pulmonary congestion at discharge was defined as
the presence of B-lines in the LUS exam in absence of rales in
the auscultation. In order to select a cut-off of B-lines, we
employed the area under the ROC curve to identify the best
number of them to predict the primary outcome applying
the Youden criteria (see Supporting Information, Figure S1).
Thus, subclinical pulmonary congestion at discharge was de-
fined as the presence of ≥5 B-lines in the LUS test in absence
of rales in the auscultation. For this post-hoc analysis, pa-
tients were compared according to the presence of clinical
(rales in auscultation) or subclinical pulmonary congestion
at discharge, irrespective of the intervention received in the
LUS-HF trial.
Statistical analysis
Continuous variables are reported as the mean ± standard
deviation, or median and interquartile range, as appropriate.
Differences in continuous variables were tested by ANOVA
or Student’s t-test for independent samples. Categorical vari-
ables were presented as frequency and percentage. Differ-
ences in the categorical variables were assessed by the χ2
test or by Fisher’s exact test. To identify the factors related
with the presence of subclinical pulmonary congestion at
discharge, a stepwise multivariable logistic regression was
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performed. Time to the primary outcome was evaluated
with the use of Kaplan–Meier curves. A propensity score
to determine the likelihood of having subclinical pulmonary
congestion was created including age, renal insufficiency,
atrial fibrillation, anaemia, NYHA class, NT-proBNP levels,
and the presence of systemic clinical congestion (oedema,
jugular ingurgitation, and hepatomegaly). Cox proportional
hazards models were performed to analyse the prognostic
role of the presence of subclinical pulmonary congestion ad-
justed by the propensity score and the intervention group.
The assumption of proportionality of hazards was tested
based on Schoenfeld residuals. Two-sided significance levels
of 0.05 were used in all analyses. Data were analysed using
STATA SE Version 13.0 (StataCorp LLC, College Station, TX,
USA).
Results
Prevalence of pulmonary congestion at discharge
and clinical characteristics of the study
population
Out of 123 patients included in the LUS-HF trial from 10 No-
vember 2016 to 19 June 2018, 100 (81%) were discharged
without rales in the auscultation. In this subgroup of patients
considered clinically without pulmonary congestion, LUS test
detected ≥5 B-lines in 41 patients. Therefore, the prevalence
of subclinical pulmonary congestion at discharge in the study
population was 33% (Figure 1). This prevalence decreased sig-
nificantly during the follow-up (Figure 2, Panel A), especially
Figure 1 (A) LUS protocol with eight scan sites, four in each hemithorax; (B) example of B-lines; (C) Flow-chart study according to the presence of rales
and ≥5 B-lines in the LUS exam. HF, heart failure; LUS, lung ultrasound.
Figure 2 (A) Prevalence at discharge and evolution of the pulmonary congestion patterns during the 6- month follow-up. (B) Short-term evolution of
the pulmonary congestion in patients with subclinical pulmonary congestion at discharge. SPC, subclinical pulmonary congestion.
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because of an early increase in the proportion of patients
with rales at the 15 day visit. In fact, nearly 50% of patients
with subclinical pulmonary congestion at discharge devel-
oped clinical signs of lung fluid overload before the first am-
bulatory check-up (Figure 2, Panel B).
Table 1 compares the clinical characteristics of the study
population according to the presence of pulmonary conges-
tion at discharge. Briefly, patients with subclinical pulmonary
congestion were mostly male, older, and had more cardiovas-
cular risk factors and comorbidities than those without sub-
clinical pulmonary fluid overload. Moreover, they had
higher frequency of prior HF history, ischemic heart disease,
atrial fibrillation, and a more advanced HF stage reflected
by higher NYHA class, plasma levels of natriuretic peptides,
and other markers of residual congestion in physical examina-
tion. Indeed, patients with subclinical pulmonary congestion
were discharged more frequently on loop diuretics and at a
higher dose than those without subclinical pulmonary con-
gestion. Overall, patients with subclinical pulmonary conges-
tion at discharge represented an intermediate HF severity
group, between patients without rales and no B-lines in the
LUS exam and subjects with clinically detectable congestion.
Factors related to the presence of subclinical
pulmonary congestion
Among patients without rales, anaemia [odds ratio (OR) 8.60;
95% confidence interval (CI): 2.25–32.89], NYHA III class
(3.13; 95% CI: 1.08–9.04), and NT-proBNP (per each
100 ng/L increase) (OR 1.04; 95% CI: 1.02–1.06) were the in-
dependent factors related with the presence of subclinical
pulmonary congestion at discharge (Table 2) after the multi-
variable analysis. Figure S2 shows the area under the ROC
curve of this model (0.829; 95% CI: 0.75–0.91).
Prognostic impact of subclinical pulmonary
congestion at discharge
Patients with subclinical pulmonary congestion at discharge
presented a higher incidence of the primary outcome during
the 6- month follow-up than those without subclinical pulmo-
nary congestion [19 (46%) vs. 9 (15%), P < 0.001, respec-
tively]. Moreover, this difference could be attributed to a
higher HF admission rate in the group of patients with sub-
clinical pulmonary congestion [15 (37%) vs. 4 (7%),
P = 0.001, respectively]. Although there was not a significant
difference in death rates between groups, a trend to a higher
mortality rate was observed in patients with subclinical pul-
monary congestion [3 (7%) vs. 0 (0%), P = 0.066, respectively].
Interestingly, outcome rates between patients with subclini-
cal pulmonary congestion and patients with rales at discharge
were similar as is shown in Table 3.
After adjusting by a propensity score including age, renal
insufficiency, atrial fibrillation, anaemia, NYHA class,
NT-proBNP levels, the presence of systemic clinical conges-
tion (oedema, jugular ingurgitation, and hepatomegaly), and
the group intervention (LUS-guided strategy), the presence
of subclinical pulmonary congestion at discharge was a risk
factor for the occurrence of primary outcome (HR 2.63; 95%
CI: 1.08–6.41, P = 0.033), similar to being discharged with
rales (HR 2.69; 95% CI: 1.03–7.01, P = 0.043). Figure 3 illus-
trates the Kaplan–Meier curves for the occurrence of the pri-
mary outcome. Interestingly, the survival curves for patients




This is the first study describing the prevalence and prognosis
of the subclinical pulmonary congestion at discharge in pa-
tients admitted for ADHF based on LUS criteria. Our results
showed that up to 40% of patients considered ‘lung-dry’ ac-
cording to the auscultation presented subclinical fluid over-
load detected by LUS. This unnoticed clinical condition was
observed more frequently in patients with anaemia, higher
NT-proBNP levels, and in those with a higher NYHA class
and implied a worse prognosis at 6- month follow-up, compa-
rable with those with clinical pulmonary congestion.
Prognosis of residual congestion in heart failure
Fluid congestion is still present before discharge in up to half
of ADHF patients, and the majority of those who are
discharged without any clinical sign of fluid retention will de-
velop it at short term.4 Moreover, pulmonary congestion at
discharge and early recurrence after are both associated with
a worse prognosis. Thus, a proper lung decongestion therapy
during HF hospitalization and a close clinical monitoring dur-
ing the first weeks after discharge are main goals for both cli-
nicians and HF care pathways.14,15 Our results highlight this
clinical situation, showing that up to 50% of patients were
discharged clinically fluid overloaded or with subclinical pul-
monary congestion. Furthermore, half of patients developed
rales before 2 weeks in the latest group.
Evaluation and monitoring of fluid excess status in patients
admitted for ADHF is currently based on clinical history, phys-
ical examination, chest X-ray, and natriuretic peptides.5 How-
ever, all these have inherent substantial inter-observer
variability and may be non-specific,6,16 and plasma levels of
biomarkers have a limited capacity to assess quantitatively
the extent of fluid retention.17 Right heart catheterization
and chest-computed tomography are much more accurate
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Table 1 Clinical characteristics of the study population according to the presence of pulmonary congestion at discharge
Without subclinical pulmonary
congestion (n = 59; 48%)
With subclinical pulmonary
congestion (n = 41; 33%) P value
With clinical pulmonary
congestion (n = 23; 19%)
P
valuea
Age (years) 65 ± 14 70 ± 10 0.051 75 ± 9 0.002
Male sex 41 (69) 30 (73) 0.690 18 (78) 0.720
BMI (kg/m2) 27 ± 5 26 ± 6 0.224 28 ± 5 0.354
Cardiovascular risk factors
Hypertension 38 (64) 31 (76) 0.234 20 (87) 0.104
Dyslipidaemia 39 (66) 29 (71) 0.625 16 (70) 0.878
Diabetes 19 (32) 18 (44) 0.233 13 (56) 0.115
Smokers or former smoker 34 (57) 30 (63) 0.131 14 (61) 0.294
Comorbidities
COPD 12 (20) 11 (27) 0.448 8 (35) 0.383
Renal insufficiencyb 12 (20) 22 (54) 0.001 12 (52) <0.001
Stroke 10 (17) 6 (15) 0.756 3 (13) 0.894
Anaemiac 4 (7) 13 (32) 0.001 8 (35) 0.002
Charlson index 2.4 ± 1.6 3.0 ± 1.6 0.073 3.0 ± 1.5 0.064
Past CV history
Previous HF 24 (41) 29 (71) 0.003 15 (65) 0.007
HF admissions in prior year 16 (27) 18 (44) 0.081 10 (43) 0.157
Ischaemic HF aetiology 22 (37) 20 (49) 0.252 12 (52) 0.353
Atrial fibrillation 26 (44) 26 (63) 0.057 16 (70) 0.050
Type of HF 0.667 0.197
HFrEF 31 (53) 25 (63) 12 (52)
HFmrEF 15 (26) 8 (20) 2 (9)
HFpEF 12 (21) 7 (18) 9 (39)




113 ± 19 112 ± 17 0.657 111 ± 16 0.789
Heart rate (bpm) 68 ± 10 70 (13) 0.585 66 ± 10 0.411
NYHA class
II 47 (80) 21 (51) 0.002 14 (61) 0.009
III 10 (17) 20 (49) 9 (39)
6MWT (m) 374 ± 108 320 ± 103 0.019 277 ± 101 0.001
Minnesota LWHF 55 ± 23 54 ± 21 0.853 48 ± 21 0.429
eGFR (mL/kg/min/1.73 m2) 71 ± 24 55 ± 23 0.001 57 ± 22 0.002
Albumin (g/L) 40 ± 4 38 ± 3 0.023 38 ± 3 0.026
Bilirubin (umol/L) 15 ± 8 15 ± 8 0.645 14 ± 7 0.629
GGT (UI/l) 44 (32–108) 68 (29–100) 0.908 47 (23–75) 0.569
NT-proBNP (ng/L) 1,071 (621–1947) 3,235 (1,559–5,799) <0.001 3,088(1,073–6,086) <0.001
Jugular ingurgitation 3 (5) 11 (27) 0.002 48 (11) <0.001
Leg oedema 3 (5) 8 (20) 0.023 10 (44) <0.001
Hepatomegaly 3 (5) 11 (27) 0.002 8 (35) 0.001
Any sign of clinical
congestion
9 (15) 17 (41) 0.003 23 (100) <0.001
No signs of clinical
congestion
50 (85) 24 (59) 0.003 0 (0) <0.001
Number of LUS B-lines 2 (1–3) 7 (6–13) <0.001 7 (5–9) <0.001
Treatment at discharge
Loop diuretics 36 (61) 36 (88) 0.011 22 (97) <0.001
Mean furosemide dose or
equivalent (mg/day)
22 ± 24 53 ± 31 <0.001 56 ± 26 <0.001
Thiazide diuretics 3 (5) 0 (0) 0.341 1 (4) 0.607
ACE inhibitors/ARB 46 (78) 36 (88) 0.208 17 (74) 0.321
Sacubitril/valsartan 3 (5) 1 (2) 0.963 0 (0) 0.475
Beta-blocker 51 (86) 32 (78) 0.272 21 (91) 0.318
Mineralocorticoid antagonist 37 (63) 25 (61) 0.860 12 (52) 0.676
Implantable cardioverter-
defibrillator
7 (12) 8 (20) 0.292 5 (22) 0.435
Cardiac resynchronisation
therapy
3 (13) 2 (5) 0.337 3 (13) 0.493
Abbreviations: 6MWT, 6 min walk test; ACE inhibitor, angiotensin converting–enzyme inhibitor; ARB, angiotensin-receptor blocker; BMI,
body mass index; COPD, chronic obstructive pulmonary disease; CV, cardiovascular; eGFR, estimated glomerular filtration rate (Modifica-
tion of Diet in Renal Disease Study formula); HF, heart failure; HFmrEF, heart failure with mid-range ejection fraction; HFrEF, heart failure
with reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; LVEF, left ventricular ejection fraction; LUS, lung ul-
trasound; Minnesota LWHF, Minnesota Living With Heart Failure quality of life scale; NT-proBNP, amino terminal pro brain natriuretic pep-
tide; NYHA, New York Heart Association.
Data are expressed as number (%), mean ± standard deviation, or median (interquartile range), as appropriate.
aP value refers to the comparison of the three groups.
bRenal insufficiency refers to estimated glomerular filtration rate <60 mL/min/1.73 m2.
cAnaemia refers to haemoglobin <13 g/dL in man and <12 g/dL in women.
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methods to assess pulmonary fluid overload, but both cannot
be used repeatedly in the day-to-day clinical practice. Thus,
LUS emerges as a promising predictive test easy to perform,
non-invasive, and cheap. Indeed, several studies have re-
ported the prognostic capacity of the presence of B-lines in
HF,7–10,18–23 although none of them has analysed the perfor-
mance of B-lines in the absence of other markers of HF con-
gestion. To the best of our knowledge, this is the first study
showing the prognostic capacity of the presence of B-lines
in patients in whom their treating physicians considered them
properly lung decongested. From that perspective, subclinical
pulmonary congestion seems to have similar deleterious ef-
fect to overt clinical pulmonary congestion, with more than
two-fold higher risk of the primary outcome.
How should subclinical pulmonary congestion be
defined?
There is not a standardized definition for subclinical pulmo-
nary congestion. Previous authors have reported several
cut-off values for B-lines with prognostic significance accord-
ing to the LUS protocol performed and the clinical
setting.9,10,19,21,22,24,25 An expert consensus document was
recently released describing the checklist for quantification
of pulmonary congestion by LUS in HF,13 but no specific num-
ber of B-lines was proposed. Our proposal is based on the
fact that ≥5 B-lines at discharge showed the best discriminat-
ing value for the event risk.
Clinical implications
Hospital readmission of patients with HF is a major public
health problem, and residual pulmonary congestion at dis-
charge is one of the leading responsible conditions. In last
years, LUS has emerged as an attractive tool in HF because
of it is a rapid point-of-care test with a fast learning curve
and a high inter-observer agreement.1,26,27 Moreover, our
group recently showed that a LUS-guided strategy signifi-
Table 2 Independent predictors for subclinical pulmonary
congestion




Anaemia 8.60 (2.25–32.89) 0.002




Abbreviations: NT-proBNP, amino terminal pro brain natriuretic
peptide; NYHA, New York Heart Association.
Table 3 Outcomes according to the presence of pulmonary congestion at discharge
Without subclinical pulmonary
congestion (n = 59; 48%)
With subclinical pulmonary
congestion (n = 41; 33%) P value
With clinical pulmonary
congestion (n = 23; 19%)
P
valuea
Primary outcome 9 (15) 19 (46) <0.00111 (48) <0.001
HF admission 4 (7) 15 (37) <0.0018 (35) <0.001
Urgent visit for
worsening HF
6 (10) 6 (15) 0.499 4 (17) 0.636
Death 0 (0) 3 (7) 0.066 2 (9) 0.038
Abbreviation: HF, heart failure. Data are expressed as number (%).
aP value refers to the comparison of the three groups.
Figure 3 Kaplan–Meier survival curves for the occurrence of the primary endpoint according to the presence of subclinical pulmonary congestion at
discharge. SPC, subclinical pulmonary congestion.
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cantly improved the combined endpoint of urgent visit, hos-
pitalization for worsening HF, and death during a 6 month
follow-up in patients after HF admission.11 Then, it is conceiv-
able that adding LUS to clinical practice will reinforce the abil-
ity of clinicians to promptly detect and treat fluid overload
and, ultimately, improve the prognosis of patients with HF.
In addition, we have identified that patients with anaemia,
higher NYHA class, and high levels of natriuretic peptides at
discharge are at risk for presenting residual lung congestion
and therefore, require a close follow-up.
Study limitations
The single-centre design of this study may hamper the
broader applicability of our results. However, the wide inclu-
sion criteria and the feasibility of the follow-up protocol sup-
port the assumption that the LUS technology can be applied
in other centres. The 5 B-lines cut-off based on a 2 s clip
length could underestimate the number of B-lines, and there-
fore, further studies are needed to be validated for longer clip
lengths and higher-end ultrasound systems in special popula-
tions such as obese patients.28,29 As this is a post-hoc analysis,
we cannot exclude a higher rate of false positives because of
multiple testing and possible selection bias. We consider our
study as hypothesis generating and acknowledge the need
of validation in a prospective trial, especially with the calcu-
lated cut-off of 5 B-lines.
Conclusions
Up to 40% of patients considered ‘dry’ according to pulmo-
nary auscultation presents subclinical congestion at hospital
discharge that can be detected by LUS and implies a worse
prognosis at 6 month follow up. Comorbidities, high values
of natriuretic peptides, and higher NYHA class are the factors
related with its presence.
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